Literature DB >> 10170454

Why training is the key to successful guideline implementation.

A D Paltiel1, P J Neumann.   

Abstract

The market for pharmacoeconomic analysis is rapidly expanding. Demand for experienced investigators seems to have outpaced the capacity of both the academic community and industry to train qualified practitioners. The result is that many professionals charged with producing and using cost-effectiveness and other drug-related economic evaluation studies may lack the basic skills required to carry out their duties. This, in turn, raises concerns regarding the credibility and integrity of the field as a whole. In our opinion, the adoption of self-imposed practice guidelines is a necessary first step in confronting these issues. However, the power of guidelines to promote responsible practice will be limited by the technical preparation of the analysts charged with adhering to them. A long term solution requires a collaborative commitment, on the part of both the academic community and the private sector, to targeted graduate training in pharmacoeconomic methods, and to the provision of ample opportunities for continuing professional education.

Mesh:

Year:  1997        PMID: 10170454     DOI: 10.2165/00019053-199712030-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  24 in total

1.  Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine.

Authors:  D Meltzer; M Johannesson
Journal:  Med Decis Making       Date:  1999 Oct-Dec       Impact factor: 2.583

2.  The FDA's regulation of pharmaceutical communications in the context of managed care: a suggested approach.

Authors:  B N Kuhlik
Journal:  Food Drug Law J       Date:  1995       Impact factor: 0.619

3.  Cost-effectiveness analysis: obstacles to standardisation and its use in regulating pharmaceuticals.

Authors:  B R Luce
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

4.  Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America.

Authors:  K Clemens; R Townsend; F Luscombe; J Mauskopf; J Osterhaus; J Bobula
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

Review 5.  Interpretation of "cost-effective" and soundness of economic evaluations in the pharmacy literature.

Authors:  J T Lee; L A Sanchez
Journal:  Am J Hosp Pharm       Date:  1991-12

6.  The journal's policy on cost-effectiveness analyses.

Authors:  J P Kassirer; M Angell
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

Review 7.  Are methods for estimating QALYs in cost-effectiveness analyses improving?

Authors:  P J Neumann; D E Zinner; J C Wright
Journal:  Med Decis Making       Date:  1997 Oct-Dec       Impact factor: 2.583

8.  Economic analysis of health care technology. A report on principles. Task Force on Principles for Economic Analysis of Health Care Technology.

Authors: 
Journal:  Ann Intern Med       Date:  1995-07-01       Impact factor: 25.391

9.  Health care CBA/CEA: an update on the growth and composition of the literature.

Authors:  A Elixhauser; B R Luce; W R Taylor; J Reblando
Journal:  Med Care       Date:  1993-07       Impact factor: 2.983

10.  The role of colleges of pharmacy in meeting the pharmacoeconomic needs of the pharmaceutical industry: a conference report.

Authors:  J R Draugalis; S J Coons
Journal:  Clin Ther       Date:  1994 May-Jun       Impact factor: 3.393

View more
  1 in total

Review 1.  Education in pharmacoeconomics: an international multidisciplinary view.

Authors:  Karen L Rascati; Michael F Drummond; Lieven Annemans; Peter G Davey
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.